Novo Nordisk A/S has raised its sales forecast for 2019 following the strong performance of its glucagon-like peptide-1 (GLP-1) analog, Ozempic (semaglutide) for diabetes in the first nine months of the year. Group sales are expected to increase by 5% to 6% at constant exchange rates compared with earlier expectations for a rise of 4% to 6%. In the first nine months, Ozempic sales reached DKK 6.9 billion (€920 million), bringing its US market share for patients starting a drug for the first time up to 37%.
